“The current stockpile of smallpox vaccine is a second-generation vaccine and is intended for the purpose of preparing for ...

The registrational trial is expected to support the approval for Bavarian’s mpox/smallpox vaccine use in children between two ...

Unverified data about events after vaccinations is not evidence that the vaccine caused the event, as suggested in social ...

The trial will be conducted in the Democratic Republic of the Congo in partnership with Emergent BioSolutions.

This is not the case with the vaccine devised to combat smallpox or variola virus. The smallpox vaccine is not a form of variola virus, but a preparation of vaccinia (a form of cowpox) virus.

Emergent BioSolutions has been given FDA approval to extend the indications for its smallpox vaccine ACAM2000 to include the prevention of mpox, currently deemed a public health emergency by the WHO.

Press Release - A drug currently approved for smallpox in the U.S. will undergo clinical trials to treat patients infected by the Mpox viruswho are at risk of severe complications in the Democratic ...

WHO’S SHOWING UP EARLY? Trump had better hope that his—ah— unorthodox appeal to female voters is paying off. Politico reports ...

It said the remaining smallpox vaccine doses were "being administered at pace" to contain cases. Most Scottish cases had London or Europe travel links and were in men who are gay, bisexual or have ...

Bavarian Nordic is running a Phase II trial (NCT06549530) to evaluate the immunogenicity and safety of the Jynneos vaccine in children from two years to less than 12 years of age compared to adults ...

Also Read: Emergent BioSolutions Confirms Orders Worth $400M Related To Smallpox, Mpox Vaccines Revenues from Anthrax MCM ...

Results from this study could support an extension of the current approval of MVA-BN to include children from 2 years of age ...